AVID200 (Fc-TβRII): A phase Ib clinical trial (NCT03895112) [436] explored the safety and therapeutic potential of AVID200 (Fc-TβRII), which traps TGF-β1 and TGF-β3, for myelofibrosis (MF), a clonal myeloproliferative neoplasm. This evidence concerns the gene TGFBR2 and myelofibrosis.